Validation for capture anion exchange chromatography process in r-hGH manufacturing

Process Biochemistry

Volumn 43, Issue 8, 2008, Pages 808-815

  Min, Byeong Jo ^a   Kang, Seong Woo ^a   Song, Yoon Seok ^a   Lee, Jong Ho ^a   Kim, Seung Wook ^a   Park, Chulhwan ^b   Kim, Chan Wha ^a  

^a Korea University   (South Korea)

^b Kwangwoon University   (South Korea)

Author keywords

Acceptance criteria; Anion exchange chromatography; Escherichia coli; Human growth hormone (hGH); Process validation; Purification

Indexed keywords

(E ,3E) PROCESS; (R ,S ,S) POLICY; ACCEPTANCE CRITERIA; ANION CHROMATOGRAPHY; ANION-EXCHANGE CHROMATOGRAPHY; BUFFER SOLUTIONS; ELSEVIER (CO); INCLUSION BODIES; MANUFACTURING PROCESSES; OPERATION PROCEDURE; SEPHAROSE;

ESCHERICHIA COLI;

EID: 46849091762     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2008.03.011     Document Type: Article

References (21)

1. Niall H.D., Hogen M., Sauer R., Rosenblum I.Y., and Greenwood F.C. Evolution of the structure of the growth hormone and prolactin family. In: Schreibman M.P., Scanes C.G., and Pang P.K.T. (Eds). The endocrinology of growth, development, and metabolism in vertebrates (1971), Academic Press, New York 13-35
2. De Vos A.M., Ultsch M., and Kossiakoff A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255 (1992) 306-312
3. Goeddel D.V., Heynecker H.L., Hozumi T., Arentzen R., Itakura K., Yansura D.G., Ross M.J., Miozzari G., Crea R., and Seeburg P.H. Direct expression in E. coli of a DNA sequence coding for human growth hormone. Nature 281 (1979) 544-548
4. Ikehara M., Ohtsuka E., Tokunaga T., Taniyama Y., Iwai S., Kitano K., Miyamoto S., Ohgi T., Sakuragawa Y., Fujiyama K., Ikari T., Kobayashi M., Miyake T., Shibahara S., Ono A., Ueda T., Tanaka T., Baba H., Miki T., Sakurai A., Oishi A., Chisaka O., and Matsubara K. Synthesis of a gene for human growth hormone and its expression in E. coli. Proc Natl Acad Sci USA 81 (1984) 5956-5960
5. Chang N.C., Rey M., Bochner B., Heynecker H., and Grey G. High-level secretion of human growth hormone by E. coli. Gene 55 (1987) 189-196
6. Tokungawa T., Iwai S., Gomi H., Kodama K., Ohtsuka E., Ikehara M., Chisaka O., and Matsubara K. Expression of a synthetic human growth hormone gene in yeast. Gene 39 (1985) 117-120
7. Hahm M.S., and Chung B.H. Secretory expression of human growth hormone in Saccharomyces cerevisiae using three different leader sequences. Biotechnol Bioprocess Eng 6 (2001) 306-309
8. Olson K.C., Fenno J., Lin N., Harkins R.N., Snider C., Kohr W.H., Ross M.J., Fodge D., Prender G., and Stebbing N. Purified human growth hormone form E. coli is biologically active. Nature 293 (1981) 408-411
9. Hathaway D. Growth hormone: challenges and opportunities for the biotechnology sector. J Anti-aging Med 5 (2002) 57-62
10. Jacob L., and Frech C. Ion-exchange chromatography in biopharmaceutical manufacturing. In: Subramanian G. (Ed). Bioseparation and bioprocessing (2007), Wiley-VCH, Germany 125-150
11. Walsh G. Biopharmaceuticals-biochemistry and biotechnology (2003), John Wiley & Sons Ltd., England p. 93-187
12. US Food and Drug Administration Center for Drugs and Biologics and Center for Devices and Radiological Health. Guideline on General Principles of Process Validation. May 1987.
13. Code of Federal Regulations. Title 21, Part 211.110. Sampling and testing of in-process materials and drug products. 1 April 1998.
14. Chapman KG. A history of validation in the United States. Part I. Pharm Technol October (1991) 82-96
15. Alsaker K.V., Paredes C.J., and Papoutsakis E.T. Design, optimization and validation of genomic DNA microarrays for examining the Clostridium acetobutylicum transcriptome. Biotechnol Bioprocess Eng 10 (2005) 432-443
16. Rathore A.S., and Sofer G. Process validation in manufacturing of biopharmaceticals-guidelines, current practices, and industrial case studies (2005), Taylor & Francis, New York
17. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration. "Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-product Endotoxin Test for Human and Aminal Parenteral Drugs, Biological Products, and Medical Devices";1987.
18. Lee S.H., Kim J.S., and Kim C.W. Optimization of buffer conditions for the removal of endotoxins using Q-sepharose. Process Biochem 38 (2003) 1091-1098
19. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 18 (2003) 1257-1259
20. Champion K., Madden H., Dougherty J., and Shacter E. Defining your product profile and maintaining control over it. Part 2. Challenges of monitoring host cell protein impurities. Bioprocess Int 3 (2005) 52-57
21. Richter A., and Katterle B. Removal and analysis of contaminants and impurities. In: Subramanian G. (Ed). Bioseparation and bioprocessing (2007), Wiley-VCH, Germany 383-410